Description: Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Home Page: www.gaintherapeutics.com
GANX Technical Analysis
4800 Montgomery Lane
Bethesda,
MD
20814
United States
Phone:
301 500 1556
Officers
| Name | Title |
|---|---|
| Dr. Khalid Islam Ph.D. | Founder & Chairman |
| Mr. Matthias Alder LIC. IUR., LL.M. | COO, CEO & Director |
| Mr. Salvatore Calabrese | CFO & Corp. Sec. |
| Dr. Xavier Barril Ph.D. | Chief Technology Officer |
| Dr. Manolo Bellotto Ph.D. | GM & Chief Strategy Officer |
| Dr. Ana Maria Garcia-Collazo Ph.D. | Head of Research |
| Dr. Natalia Perez-Carmona Ph.D. | Head of Biology |
| Dr. Joanne Taylor Ph.D. | Sr. VP of Research & Scientific Advisor |
| Dr. Terenzio Ignoni Pharm.D. | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.636 |
| Price-to-Sales TTM: | 210.9717 |
| IPO Date: | 2021-03-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 25 |